Market data and research context for informational purposes. Not investment advice.
Indicators from the 2026-11-19 daily bar; Bollinger %B and the average rows compare the latest price with those values. Prices in USD.
Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders.